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Abstract
Congenital Cytomegalovirus infection (cCMV) is the leading infection in determining perma-
nent long-term impairments (LTI), and its pathogenesis is largely unknown due to the com-
plex interplay between viral, maternal, placental, and child factors. The cellular activity,
considered to be the result of the response to exogenous and endogenous factors, is cap-
tured by the determination of gene expression profiles. In this study, we determined whole
blood transcriptomes in relation to cCMV, CMV viral load and LTI development at 6 years of
age by using RNA isolated from neonatal dried blood spots (DBS) stored at room tempera-
ture for 8 years. As DBS were assumed to mainly reflect the neonatal immune system, par-
ticular attention was given to the immune pathways using the global test. Additionally,
differential expression of individual genes was performed using the voom/limma function
packages. We demonstrated feasibility of RNA sequencing from archived neonatal DBS of
children with cCMV, and non-infected controls, in relation to LTI and CMV viral load. Despite
the lack of statistical power to detect individual genes differences, pathway analysis sug-
gested the involvement of innate immune response with higher CMV viral loads, and of anti-
inflammatory markers in infected children that did not develop LTI. Finally, the T cell exhaus-
tion observed in infected neonates, in particular with higher viral load, did not correlate with
LTI, therefore other mechanisms are likely to be involved in the long-term immune dysfunc-
tion. Despite these data demonstrate limitation in determining prognostic markers for LTI by
means of transcriptome analysis, this exploratory study represents a first step in unraveling
the pathogenesis of cCMV, and the aforementioned pathways certainly merit further
evaluation.
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Introduction
Human Cytomegalovirus (CMV) is one of the most common causes of congenital viral
infection, leading to a significant number of children with permanent disabilities. The overall
birth prevalence of congenital CMV infection (cCMV) in industrialized countries is between
0.6% and 0.7% [1, 2]. Among the congenitally infected infants, 12.7% are estimated to have
symptoms at birth, ranging from mild, such as petechiae, to severe, such as microcephaly
[1, 2]. An estimated 40–58% of these symptomatic children develop permanent long-term dis-
abilities, such as hearing loss, cognitive and motor developmental delay [1]. Although symp-
tomatic neonates have a considerable risk to develop permanent long-term impairments
(LTI), approximately 13% of the asymptomatic children will also develop permanent LTI
[1]. Despite the current insights into the clinical outcome of cCMV, the multifactorial pro-
cess that determines whether a child is symptomatic at birth or will develop LTI is largely
unknown.
The control of cCMV, and cCMV-related disease, may be the result of a complex interac-
tion between viral, maternal, placental, fetal and child factors [3]. The clinical impact of cCMV
has mainly been evaluated in relation to maternal factors, such as the CMV immune status
before pregnancy or the time of vertical transmission. The vertical transmission rate is higher
among women without prior CMV infection than among previously exposed women [2], indi-
cating that pre-existing immunity can be protective. Vertical transmission occurring in the
first 20 weeks of pregnancy leads to a worse clinical outcome than transmission occurring later
in pregnancy [4, 5]. The latter is probably related to an increased susceptibility to infection due
to fetal organogenesis, and a still developing fetal immune system. Although the pathogenesis
of LTI is poorly understood, the fetal and neonatal immune system likely play an important
role in controlling the infection, thereby influencing LTI development [3]. Several studies have
demonstrated a CMV-specific adaptive immune response in congenitally infected children,
such as γδ and αβ T cells or B cells [6–10], as well as an innate immune response [11, 12]. How-
ever, only few studies have evaluated these responses in relation to clinical outcome at birth,
whereas the majority has not done so in relation to LTI development. An increase of NK cells
was observed in congenitally infected children, and their frequency was higher in those who
were symptomatic at birth [11]. In proteomic studies, an increase of macrophage-derived cyto-
kines was observed in congenitally infected children, whereas an increase of β-defensin was
observed in those who were asymptomatic at birth [12]. Moreover, the cytokine profile of con-
genitally infected children, both asymptomatic and symptomatic, was different from that of
their mothers with primary infection [13].
The gene expression profile captures a snapshot of the cellular activity which is the result of
the response to genetic, environmental and epigenetic factors [14]. After having established,
through forensic studies, that reliable RNAs can be extracted from dried stains, a considerable
amount of studies focused on neonatal dried blood spots (DBS) because they represent an
important archived, and readily accessible specimen to study factors of disease development.
Indeed, DBS are usually collected at birth for the screening of rare genetic metabolic disorders,
and are stored for several years [15]. Previous studies have shown that quantitative RNA mea-
surements, either with microarrays or RNA-seq, can be performed on neonatal DBS stored at
room temperature for up to 9 years [14, 16–18]. Additionally, since the transcriptional profiles
of RNA derived from DBS in mice, stored for several months at room temperature, correlated
with those from fresh whole blood [19], we assumed this may also be the case in humans. The
transcriptome varies according to the cell types studied, and certain RNA markers are tissue-
specific. Tissue-specific RNA molecules have been successfully extracted from blood and saliva
stains, dried at room temperature for up to 16 years, and used for genome-wide expression
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analysis [20, 21]. Since DBS are produced by spotting whole blood on filter paper, they were
assumed to mainly reflect the neonatal immune system.
The aim of this exploratory study was to evaluate the feasibility of transcriptome analysis
from archived neonatal DBS in relation to cCMV and LTI development. In particular, we
wanted to determine whether the neonatal immune system at birth may be a determinant of
LTI development at 6 years of age. This would provide insights into the immune regulation of
cCMV, and, by identifying prognostic markers for clinical outcome, could provide the means
to introduce the long-debated newborn screening program for CMV in DBS by defining sub-
groups of infants that would benefit from clinical and audiological follow-up, and possibly
antiviral treatment [22]. Our investigations revealed that transcriptome analysis of RNA from
neonatal DBS stored at room temperature for 8 years of a nation-wide retrospective cohort of
children with cCMV and controls is possible, and could potentially be used to unravel the
pathogenesis of cCMV and CMV-related disease.
Materials and methods
Study population and clinical data
A previously described nationwide, retrospective cohort was used in this study [23]. The co-
hort was derived from a total group of 31,484 children, born in 2008 in the Netherlands, which
was retrospectively tested for cCMV by PCR of CMV DNA in neonatal DBS at five years of
age. In total, 156 children (0.5%) were diagnosed with cCMV. Clinical data were retrieved
from 133 congenitally CMV-infected children and from 274 non-infected children. Children
were defined as symptomatic at birth if they had one or more of the following signs or symp-
toms in the neonatal period: prematurity, being small for gestational age, microcephaly,
hepato- or splenomegaly, generalized petechiae or purpura, hypotonia, abnormal laboratory
findings (elevated liver transaminases, hyperbilirubinemia, neutropenia or thrombocytope-
nia), cerebral ultrasound abnormalities, ophthalmologic abnormalities or neonatal hearing
impairment. LTI was defined as the presence of impairment in one or more domain (hearing,
visual, neurological, motor, cognitive and speech-language). The cCMV associated LTI in the
original cohort has been described in detail [24]. In brief, hearing impairment was defined as
sensorineural hearing loss 40 dB; visual impairment was defined as a visual acuity below 0.3;
neurological impairment included cerebral palsy, epilepsy, microcephaly, autism spectrum dis-
order and ADHD; motor developmental delay was based upon the physical therapist’s report
and if available on a score below the fifth centile in the Movement Assessment Battery for Chil-
dren; cognitive developmental delay was defined as an intelligence quotient less than or equal
to 70 if this was tested, or it was based on a diagnosis by a medical specialist; speech and lan-
guage development were assessed by the speech therapist or speech and hearing centre. Addi-
tionally, the severity of the LTI was assessed by accumulating the number of domains affected
and indicated as the presence of LTI in two or more domains. Since in this cohort maternal
seroimmunity to CMV before birth was unknown, it was assumed that cCMV infection could
have resulted from either maternal primary or secondary infection. Due to the retrospective
design of the study, there was no standardized clinical and laboratory assessment performed at
birth. Therefore, we cannot exclude the possibility that we might have misclassified some new-
borns without clinically apparent disease or with mild and transient symptoms in the asymp-
tomatic group. However, because of the Dutch child health care system, the chance of having
missed major signs or symptoms can be considered negligible [23, 24].
For the study presented in this article, DBS were selected based on the clinical outcome of
the infants, with a total of 6 CMV-negative without any clinical signs, 6 CMV-positive with
LTI and 6 CMV-positive without LTI. This study was approved by the Medical Ethics
Transcriptome of DBS from neonates with cCMV
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Committee of the Leiden University Medical Center, and all the parents of the children
included have given written informed consent for the use of clinical data and DBS.
DNA extraction from DBS and qPCR of CMV
After a first initial CMV PCR screening performed at the National Institute for Public Health
and the Environment (RIVM), a second confirmatory PCR was performed at the Leiden Uni-
versity Medical Center (LUMC) [23]. For this purpose, DNA was extracted from DBS by using
the QIAamp DNA minikit according to the previously described protocol [25]. For each test,
one full DBS was punched by using an automated DBS puncher (1296–071, Perkin Elmer-
Wallac, Zaventem, Belgium). CMV DNA amplification of a 126-bp fragment from the imme-
diate-early antigen region was performed using an internally controlled quantitative real-time
PCR, as described previously [26, 27], on the CFX96 Real-Time PCR Detection System
(BioRad, Veenendaal, The Netherlands). The PCR was performed in triplicate, and the CMV
viral load was expressed in IU/ml.
RNA extraction from DBS
One full DBS was punched using an automated DBS puncher (1296–071, Perkin Elmer-Wal-
lac, Zaventem, Belgium). RNA was extracted from DBS by using the NucleoSpin miRNA kit
(Macherey-Negel, Duren, Germany), according to the manufacturer’s instructions with a
minor modification. This included pre-incubating the DBS with 300 μl of lysis buffer ML for
30 min at 37˚C with agitation (1000 rpm) [28]. The supernatant was transferred to the
NucleoSpin Filter, and the procedure was carried out according to the manufacturer’s instruc-
tion. Small and large RNAs were purified in one fraction, without separation of small RNAs,
and a DNase treatment was used to reduce DNA contamination. The RNA was eluted in 50 μl
of RNase-free H2O, and RNA integrity was assessed using the RNA Nano 6000 Assay Kit on
the Bioanalyzer 2100 system (Agilent Technologies, CA, USA). The RNA concentration was
measured using a Qubit 2.0 flurometer (Life Technologies, CA, USA).
Library preparation and sequencing
An average amount of 185 ng of RNA was used as input material for library preparation.
Sequencing libraries were generated using the TruSeq Stranded Total RNA Sample prepara-
tion kit for Illumina (Illumina, Inc., San Diego, CA, USA) following the manufacturer’s rec-
ommendations, and index codes were added to attribute sequences to each sample. Briefly,
rRNA was depleted from total RNA using rRNA removal magnetic beads (RRB). The remain-
ing RNA was purified using RNAClean XP magnetic beads. As the RNA samples from DBS
were already fragmented, the fragmentation step was skipped in order to avoid over-fragmen-
tation. First strand cDNA was synthetized using random hexamer primers and SuperScript II
reverse transcriptase. Second strand synthesis was performed using the polymerase provided
with the kit. After adenylation of the 3’ end of the blunt-ended DNA fragments, the RNA
index adapters were ligated, and PCR was carried out using the PCR master mix and primer
cocktail provided by Illumina to amplify the DNA in the library that had adapter molecules on
both ends. Library quality was assessed using the DNA 1000 Assay kit for the Agilent Bioanaly-
zer 2100 system (Agilent Technologies, CA, USA), and the DNA amount was measured using
a Qubit 2.0 flurometer. Clustering of the index-coded samples was performed using the Illu-
mina TruSeq PE Cluster Kit v3 (cBot-HS) according to the manufacturer’s instructions. After
cluster generation, the libraries were sequenced on the Illumina HiSeq 2000 platform (6 sam-
ples per lane), and 76 base paired-end reads were generated for the first batch (n = 6, 2 of each
group) and 50 base paired-end reads for the second batch (n = 12, 4 of each group). All 76 base
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reads were trimmed to 50 bases to allow for uniform subsequent analysis across all samples,
and the batch effect was accounted for in downstream analysis. Due to lack of resources it was
not possible to sequence the whole cohort.
Read mapping to the reference genome
Sequence files were generated in FASTQ format, and all RNA sequence files were processed
using the BIOPET Gentrap pipeline version 0.7 developed at the LUMC (http://biopet-docs.
readthedocs.io/en/latest/releasenotes/release_notes_0.7.0/). The BIOPET Gentrap pipeline
consists of FASTQ pre-processing (including quality control, quality trimming and adapter
clipping), RNA-seq alignment, read and base quantification. FastQC version 0.11.2 was used
for raw read quality control. Low quality read trimming was done using sickle version 1.33
with default settings. Cutadapt version 1.9.1 with default settings was used for adapter clipping
based on the detected adapter sequences by FastQC toolkit. RNA-seq reads were aligned
against human reference genome GRCh38 using RNA-seq aligner GSNAP version 2014-12-23
with settings "—npaths 1—quiet-if-excessive". Ensembl human genome annotation version 87
was used for raw read counting. The gene read quantification step was performed using htseq-
count version 0.6.1p1 with the setting "—stranded = reverse".
Differential expression analysis: Individual genes
We identified significant gene expression differences between congenitally infected children
(n = 12) and controls (n = 6), as well as between congenitally infected children that developed
LTI (n = 6) and congenitally infected children that did not develop LTI (n = 6). Moreover, we
also assessed gene expression differences in relation to logarithm of CMV viral load treated as
continuous variable. Genes with low fragment counts were removed by requiring at least 2
fragments per million of aligned fragments to be observed in at least 2 samples. Library size
normalization factors were obtained with the trimmed mean of M-values (TMM) method
[29]. Linear modelling using Bioconductor/R package ‘limma’ [30] was performed on read
counts transformed to log-CPM values. Observational-level weights obtained from the voom
function were used to model mean-variance relationship. All three analyses were corrected for
the batch effect in the design matrix. Multiple testing correction using false discovery rate con-
trol of Benjamini and Hochberg was performed at the threshold of 0.05.
Differential expression analysis: Pathways
The Bioconductor/R package ‘global test’ designed by J. Goeman was used to evaluated differ-
ences in expression profiles of gene sets between the different groups [31]. These were a group
of congenitally infected children (n = 12) and a group of controls (n = 6). Within the group of
congenitally infected children, those that developed LTI (n = 6) and those that did not develop
LTI (n = 6). An additional analysis was performed to find gene set expression profiles depen-
dent on CMV viral load as continuous variable. This method has been shown to have more
power to detect gene sets with small effect size [29, 32, 33]. We selected a limited number of
candidate gene sets (pathways) for use in the global test, before inspecting the data using the
QuickGO browser [34]. The pathways were selected based on their putative role in the etiology
of the disease. An additional selection criterion was the specimen, i.e. DBS, which derives from
whole blood and therefore mainly reflects the neonatal immune system. These pathways were
T-, B-, and NK-cell activation, innate immune response, and inflammatory response with its
regulation. Each pathway contained from 17 to 435 genes. This analysis was performed on the
voom-transformed data. Due to the exploratory nature of this study, and to the limited num-
ber of selected pathways, no multiple testing correction was applied.
Transcriptome of DBS from neonates with cCMV
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Finally, an additional immune pathway that has emerged as one of the possible players in
limiting the immune response during cCMV is the T cell exhaustion [7]. However, this does
not exist yet as a pathway in the QuickGo browser. Therefore, based on the transcriptional def-
inition of exhaustion previously described [7, 35], and on our available data, a set of exhaustion
genes was selected. An independent sample t-test was used to evaluate the difference in the
square root of the reads per million (RPM) between the different categories. CMV+ vs CMV-,
CMV+ without LTI vs CMV+ with LTI, CMV+ low load vs CMV+ high load. In the latter, the
infected group was split in two according to the median log2 viral load measured in DBS
which was 10.2, namely low (< 10.2) and high ( 10.2) viral load groups. However, p-values
were not reported because this analysis had the sole purpose of illustrating trends.
Results
Study population and clinical data
The clinical data of the congenitally infected children included in this study, as well as of the
non-infected controls, are listed in Table 1. A total of 12 children with cCMV, and 6 without
cCMV, were included in order to assess the gene expression profile in relation to cCMV. Addi-
tionally, the 12 children with cCMV were selected in order to assess differences in gene expres-
sion in relation to LTI development. For this purpose, 6 infected children were selected, who
did not have any symptoms at birth nor LTI at six years of age, whereas the other 6 had LTI in
one or more of the following domains of impairment: neurological, motor, cognitive and
speech/language (Table 1). Five children out of those who developed LTI also had symptoms
at birth. Importantly, none of the children in the control group had symptoms at birth nor
developed LTI. Given the diversity of the specific symptoms at birth and impairments at the
age of six, the subjects were selected in order to have a similar proportion of male and female
across the groups. In this way, the influence of gender in the gene expression analysis was
limited.
Library preparation and sequencing statistics
The average number of RNA-seq read pairs per sample was 38.5 million ± 4.8 million, with
38.9 million ± 5.4 million for the CMV- samples and 38.4 million ± 4.7 million for the CMV+
samples. Within the CMV+ samples, those without LTI generated 37.6 million ± 5.9 million
paired-end reads, and those with LTI generated 39.1 million ± 3.6 million paired-end reads.
The mean RNA fragment size was 285 ± 8 bp, and the mean DNA fragment size was 165 ± 8
bp. On average, 92.25% of bases exceeded Q30. The detailed information per sample is shown
in Table 2.
Differential expression: Individual genes
Next, we determined whether any other gene could be associated with cCMV, LTI develop-
ment at 6 years of age or CMV viral load. After low count features removal, ~25% of counts
aligned on features and 18360 different genes were used in gene expression analysis. The R
package LIMMA was used for the assessment of differential expression of individual genes
between congenitally infected children (n = 12) and non-infected controls (n = 6). No statisti-
cally significant differences in gene expression were observed between the groups. We next
assessed gene expression differences in relation to cCMV clinical outcome by comparing con-
genitally infected children that developed LTI at six years of age (n = 6) to congenitally infected
children that did not develop LTI (n = 6). This analysis did not reveal any statistically signifi-
cant differences between the groups. Finally, the differences in gene expression were assessed
Transcriptome of DBS from neonates with cCMV
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in relation to the logarithm of CMV viral load as continuous variable, and no statistically sig-
nificant differences were observed.
Differential expression: Pathways
In order to evaluate whether different biological mechanisms may underlie different clinical
outcomes, a global test was performed on manually pre-selected pathways based on their puta-
tive role in the etiology of cCMV disease. The selected pathways for T-, B-, and NK-cell activa-
tion, innate immune response, and inflammatory response were assessed in relation to cCMV,
LTI development at 6 years of age and CMV viral load. The results are shown in Table 3. This
analysis revealed trend significant results in relation to CMV viral load and LTI development.
In particular, the innate immune response (p = 0.046, Fig 1) and the NK-cell activation
(p = 0.086) may be associated to CMV viral load; whereas the regulation of inflammatory
response (p = 0.077, Fig 2) to LTI development. In all cases, a small number of genes appeared
Table 1. Study population and clinical outcome.
cCMV with LTI1 cCMV no LTI2 No cCMV3
n = 6 n = 6 n = 6
Gender
Male 4 3 3
Female 2 3 3
Gestational age (weeks)4 39 (36–40) 40 (37–41) 41 (37–41)












Hearing impairment6 0 0 0
Visual impairment7 0 0 0
Neurological impairment8 3 0 0
Motor impairment9 6 0 0
Cognitive impairment10 4 0 0
Speech/language problem11 4 0 0
More than one impairment12 5 0 0
1 Congenitally infected children that develop LTI, 5 out of 6 had symptoms at birth including prematurity (n = 1),
dysmaturity (n = 1), microcephaly (n = 3)
2 Congenitally infected children that did not develop LTI, none of them had symptoms at birth
3 Non-infected controls, none of them had symptoms at birth nor LTI
4 Values are medians with minimum and maximum
5 CMV viral load measured on DBS, values are log (IU/ml) medians with minimum and maximum
6 Sensorineural hearing loss 40 decibels
7 Optic nerve atrophy or cortical visual impairment
8 Cerebral palsy (n = 1), epilepsy (n = 1), microcephaly (n = 1), autism (n = 2), ADHD (n = 1)
9 Motor impairment (fine, gross or balance) based on test or diagnosis or sensory processing disorder or
developmental coordination disorder (n = 6)
10 Cognitive impairment based on test or diagnosis (n = 4)
11 Language impairment based on test or diagnosis, speech-impairment, oral motor skill difficulties or auditory
processing disorder (n = 4)
12 Impairment in two or more domains of impairment: hearing, visual, neurologic, motor, cognitive, and speech-
language.
https://doi.org/10.1371/journal.pone.0200652.t001
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to be responsible for these trends. Several antiviral genes were positively associated with CMV
viral load, i.e. ISG15 and RSAD2, whereas the anti-inflammatory cytokine IL-4 was associated
with the congenitally infected children that did not develop LTI.
Table 2. RNA-seq data per individual.


























































































































1 ID child identification number
2 cCMV, congenital Cytomegalovirus infection; CMV+, congenitally infected children; CMV-, non-infected controls
3 f, female; m male
4 LTI, long-term impairment at 6 years of age
5 Input RNA (ng) the amount of RNA used as input material for library preparation;6 Total number of paired-end reads, total number of paired-end reads that passed
Illumina filter generated per sample
7 Total bases, total number of bases generated per sample
8 Raw bases Q10+, base calls with quality Q-scores of Q10+ (Q10 or higher) have an error probability of 0.1 (1 in 10) or less
9 Raw bases Q20+, base calls with Q20+ have an error probability of 0.01 (1 in 100) or less
10 Raw bases Q30+, base calls with Q30+ have an error probability of 0.001 (1 in 1,000) or less.
https://doi.org/10.1371/journal.pone.0200652.t002
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Finally, as previously shown by others, one of the possible mechanisms limiting the T cell
response to CMV during early life is considered to be T cell exhaustion [7]. Therefore, we won-
dered whether the same phenomenon could be observed in our cohort when comparing the
CMV- group (n = 6) to the CMV+ group (n = 12). Additionally, this pathway was assessed in
relation to CMV viral load and development of LTI at 6 years of age. For this purpose, based
on the transcriptional definition of exhaustion previously described [7, 35], as well as on our
available data, a set of genes was selected and reported in Table 4. Of these genes, the RPM
were reported for each comparison in order to observe the trend to be further explored. A
trend of increased expression of differentiation markers, mainly CD57 and transcription factor
T-bet, and of increased effector markers, primarily IFN-γ and granzyme, was observed in the
CMV+ group compared to the CMV- group (Fig 3A–3D). Furthermore, a trend of increased
expression of inhibitory markers, mainly PD-1 and LAG-3, was observed in the CMV+ group
(Fig 3A–3D). Next, the CMV+ group was split in two groups according to the median log2
viral load measured in DBS which was 10.2, namely low and high viral load groups. Compar-
ing the group with high viral load to the one with low viral load, the aforementioned observed
trends relative to differentiation, effector and inhibitory markers were more pronounced than
when comparing CMV+ to CMV-. Finally, when comparing the cCMV+ group that developed
LTI to those who did not, no striking trends were observed (Fig 3A–3D).
Discussion
This study aimed to evaluate whether transcriptome analysis by next generation RNA sequenc-
ing on DBS derived from a retrospective nation-wide cohort of children with cCMV and con-
trols is feasible, and whether useful insights could be obtained on the etiology of different
cCMV outcomes. This would allow the identification of potential biomarkers for long-term
outcome, which could provide the means to introduce the long-debated newborn screening
program for cCMV in DBS [22]. Indeed, this would define subgroups of children benefitting
from clinical, audiological follow-up, and possibly antiviral treatment.
The global test for differential expression of gene sets revealed, although only with trend sig-
nificant results, an important feature of cCMV in relation to whole blood transcriptome, i.e.
CMV viral load is the main factor to influence the pre-selected immune pathways, whereas
CMV disease seems to be secondary. In our study, numerous antiviral genes were positively
associated with CMV viral load, suggesting the involvement of the innate immune system in
Table 3. Global test analysis.
Pathways cCMV1 LTI2 CMV viral load3
p-values
Innate immune response (435 genes) 0.7064 0.432 0.046
T cell activation (51 genes) 0.375 0.203 0.195
B cell activation (30 genes) 0.367 0.125 0.254
NK cell activation (17 genes) 0.717 0.499 0.086
Inflammatory response (381 genes) 0.725 0.341 0.232
Regulation of inflammatory response (68 genes) 0.577 0.077 0.567
Negative regulation of inflammatory response (78 genes) 0.633 0.339 0.133
Positive regulation of inflammatory response (74 genes) 0.444 0.652 0.791
1 Gene sets expression differences between CMV- (n = 6) and CMV+ (n = 12)
2 Gene sets expression differences between congenitally infected children with LTI (n = 6) and without LTI (n = 6)
3 Gene sets expression differences according to CMV viral load (continuous variable).
https://doi.org/10.1371/journal.pone.0200652.t003
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response to cCMV in the newborns, in particular with higher viral loads. The fact that no strik-
ing differences were observed when comparing CMV+ to CMV-, suggests that the high viral
load is the main initiator of this expression pattern. Therefore, the presence of neonates with
low viral load in the CMV+ group may have diluted the differences between CMV+ and
CMV-. Congenitally infected children excrete CMV for several years after birth, whereas in
adults this lasts only several months [36, 37], suggesting a deficient cell-mediated immune
response in early life [38]. Therefore, it is tempting to speculate that the activation of the innate
immunity in the fetus may have an important role in controlling cCMV, however this is diffi-
cult to determine. One of the possible mechanism for this limited T cell response to CMV dur-
ing early life is considered to be T cell exhaustion [7]. In our cohort, also the exhaustion
pathway was more pronounced in the high viral load group compared to the low viral load
group, with PD-1 being the marker influenced the most, as previously shown [7]. Therefore,
also in this case the difference in exhaustion pathway between CMV+ and CMV- could have
Fig 1. Global test: Innate immune response. Innate immune response in relation to CMV viral load as continuous variable measured on DBS, p = 0.046.
The gene names of x-axes are provided in supplementary S1 Table.
https://doi.org/10.1371/journal.pone.0200652.g001
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been diluted because of the presence of low viral load individuals in the CMV+ group. How-
ever, the exhaustion pathway analysis needs further confirmation as we only reported expres-
sion trends. T cell exhaustion is characterized by loss of T cell functions, and is induced by
persistent infections [7, 35]. Primary CMV infection induces functional T cell exhaustion
in both adults and fetuses, though considerably more pronounced in the latter. As this phe-
nomenon is associated with prolonged exposure with higher viral loads, the high viral loads
reported in fetuses may be the cause of this effect [39–41]. The exhaustion may contribute to
the prolonged CMV viral excretion in the children [7]. The influence of viral load in the
immune responses has been shown before, both in humans and in the murine models of CMV
infection. Here, the degree of CMV-specific memory CD8 T cells accumulation, as well as the
phenotypic T cell profile, was influenced by the viral load [42, 43]. However, the role of CMV
viral load in the clinical outcome still remains controversial. Some studies have correlated
CMV viral load, measured in blood, with clinical outcome [44, 45], whereas others have not
[46–48]. The neonatal viral load may differ depending on the trimester of vertical transmis-
sion, or whether it was a primary maternal infection. Indeed, earlier infections may lead to a
more extensive cCMV. However, in our cohort this is impossible to establish [49]. Addition-
ally, CMV viral load in whole blood may not correlate to CMV loads in other neonatal
Fig 2. Global test: Regulation of inflammatory response. Regulation of inflammatory response in congenitally infected children that developed LTI at 6 years of age
(n = 6) and in congenitally children that did not develop LTI (n = 6), p = 0.077.
https://doi.org/10.1371/journal.pone.0200652.g002
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compartments, and therefore may not fully reflect viral replication in all affected organs and
tissues.
The molecular mechanisms of LTI development are largely unknown, though the late-onset
hearing loss is believed to be the result of a chronic productive infection throughout childhood
[50, 51]. In this context, a long-term dysfunctional immune response seems plausible, although
it cannot be excluded that such dysfunction leads to a parallel uncontrolled inflammation that
contributes to tissue damage. In studies of characterization of tissue damage in fetuses of 20–
21 weeks of gestation with cCMV, an association between the degree of tissue damage in the
brain, as well as in the inner ear, with viral load, inflammatory response and placental func-
tionality was shown [52, 53]. A dysfunctional immune response that leads to uncontrolled
viral replication, and immune-mediated damage was suggested. Therefore, a similar pathogen-
esis may be assumed when such infection becomes chronic. The exhaustion pathway that was
found in congenitally infected children, especially those with higher CMV viral load, did not
seem to correlate to clinical outcome at 6 years of age. This suggests that other mechanisms are
involved in the long-term immune dysfunction. In our cohort, when comparing congenitally
infected children that developed LTI to those infected who did not, a role for the regulation of
inflammatory responses seemed to partially contribute. Anti-inflammatory markers, such as
the cytokine IL-4, were associated with congenitally infected children that did not develop
LTI. The success of an immune response is the result of a balance between effector and regula-
tory mechanisms, therefore, the potential protective effect of IL-4 in those infected children
that did not develop LTI may lie in its anti-inflammatory property. Interestingly, in a cohort of
healthy CMV infected individuals, the CD4 T-cell response associated with a protective immu-
nity involved cytokine production of IFN, and/or IL-17, in association with IL-4 [54]. Similarly
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to IL-10, IL-4 has been shown to possess the capacity of down-regulating the production of
pro-inflammatory mediators by microglia, both in humans and in mice [55–57], and its neuro-
protective effect was associated with downregulation of brain inflammation in mice [58].
When studying the regulation of the inflammatory response in children with cCMV and com-
pare the group with LTI to that without LTI, we have to be aware that there may be other peri-
natal factors influencing the inflammatory pattern in DBS. Although we cannot fully exclude a
role for non-cCMV related perinatal factors, there was no bacterial amniotic infection or neo-
natal sepsis in all children included in this study.
Several reasons may have contributed to the fact that we did not find a strong impact of
cCMV on whole blood transcriptomes from DBS. First of all, one of the groups of congenitally
infected children did not have symptoms at birth nor LTI, which is the case in most children
with cCMV, and the clinical signs of symptoms associated with LTI are very diverse. Second of
all, in our cohort, the fetal infection may have been the result of a primary or secondary CMV
infection in the mother, and may have taken place at any time during pregnancy, especially in
Fig 3. A-D. T cell exhaustion. T cell markers identifying the exhaustion phenotype in relation to cCMV, CMV viral load and LTI development at 6 years of age. CMV-,
non-infected controls (n = 6); CMV+, congenitally infected children (n = 12); CMV+ low load, congenitally infected children with log2 CMV viral load below the
median measured in DBS which was 10.2 (n = 6); CMV+ high load, congenitally infected children with log2 CMV viral load equal to or above the median measured in
DBS (n = 6); CMV+ LTI-, congenitally infected children that did not develop LTI (n = 6); CMV+ LTI+, congenitally infected children that developed LTI (n = 6).
Boxplot: bold line, median of square root of RPM; red dot, mean of square root of RPM.
https://doi.org/10.1371/journal.pone.0200652.g003
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the asymptomatic children. Third of all, the small sample size of the groups may have led to a
lack of power both in the gene expression analysis of individual genes, as well as in the pathway
analysis. Lastly, the RNA degradation on these specimens, due to e.g. ribonucleases, pH,
humidity or UV light, may have contributed to the lack of significant differences among the
sample groups. The degradation of RNA from dried stains has been extensively studied in
forensic studies for obvious reasons, and several RNAs have been extracted from numerous
conditions [59–64]. From these studies, determinants for RNA stability appeared to be the
specimen the RNA is extracted from, and the specific RNA molecule analyzed. In the former,
the detection limit of blood-specific RNA has been shown to be lower than for other specimens
[21]. In the latter, some RNAs can be more stable in dried stains than others [21]. Secreted
RNAs, e.g. in fresh saliva, may be more susceptible to fast degradation by extracellular RNases,
and therefore are not to be expected on dried stains [20]. Importantly, for those RNAs detected
on dried blood stored at room temperature, only few genes have been demonstrated to be dif-
ferentially expressed during time [20]. Therefore, we assumed that those markers detected on
DBS in our study were less prone to degradation, and relatively stable for long periods of time.
Furthermore, the influence of RNA contamination in the downstream analysis, e.g. from skin
cells or external microorganisms, may be considered negligible as the most abundant RNAs
species come from the host whole blood [65]. Despite the fact that enough data were generated
in our study for the downstream analysis, with comparable cDNA fragment size as shown in
forensic studies [21, 59–64], we cannot exclude that fresh material may have revealed differ-
ences in expression patterns that we could not pick up.
Furthermore, due to the retrospective nature of the study, cCMV diagnosis was performed
by performing PCR of viral DNA on DBS, which in comparison with PCR on urine or saliva
has been associated with limited and variable sensitivity [66]. Therefore, a negative CMV PCR
on DBS does not fully exclude cCMV. However, it is important to note that with the relatively
high sensitivity of our CMV PCR on DBS (estimated > 85%), high specificity (> 99.9%) and
the cCMV birth prevalence of 0.5%, the chance of a CMV false-negative result is 1/1000 [23].
Therefore, it is very unlikely that a cCMV positive child ended up in our cCMV negative con-
trol group.
To the best of our knowledge, this is the first exploratory study assessing the feasibility of
transcriptome sequencing using RNA isolated from archived neonatal DBS of children with
cCMV, and non-infected controls, in relation to long-term outcome. Despite the lack of statis-
tical power to detect individual gene expression differences, the pathway analysis suggested a
potential differential gene expression in relation to CMV viral load and LTI. Therefore, this
study represents a first step in unraveling the pathogenesis of cCMV, and in identifying prog-
nostic markers for cCMV long-term outcome.
Supporting information
S1 Table. Gene names. Gene names of x-axis of Fig 1 concerning the innate immune response
in relation to CMV viral load as continuous variable.
(XLSX)
S2 Table. Read counts per gene.
(XLSX)
Acknowledgments
The CROCUS study was initiated and supported by the National Institute of Public Health
and the Environment (RIVM), we thank Marjolein Korndewal for the use of the CROCUS
Transcriptome of DBS from neonates with cCMV
PLOS ONE | https://doi.org/10.1371/journal.pone.0200652 July 19, 2018 14 / 18
study clinical data. We thank Daniela Balzereit, Simon Dökel, Alexander Kovacsovics and
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